Abstract 217: BCR-ABL tyrosine kinase inhibition combined with a novel pan BCL2 family inhibitor abrogates leukemia stem cell survival in a niche-dependent manner.
2018 ◽
Vol 504
(4)
◽
pp. 721-726
2014 ◽
Vol 124
(9)
◽
pp. 3847-3862
◽
Keyword(s):
Keyword(s):
Keyword(s):
2021 ◽
Vol 555
◽
pp. 196-201